Research Papers:

The bromodomain inhibitor IBET-151 attenuates vismodegib-resistant esophageal adenocarcinoma growth through reduction of GLI signaling

Annamil Alvarez-Trotta, Zhiqiang Wang, Elena Shersher, Bin Li, Jun Long, Ines Lohse, Claes Wahlestedt, Wael El-Rifai, David J. Robbins _ and Anthony J. Capobianco _

PDF  |  Full Text  |  Supplementary Files  |  How to cite

Oncotarget. 2020; 11:3174-3187. https://doi.org/10.18632/oncotarget.27699

Metrics: PDF 1304 views  |   Full Text 1898 views  |   ?  


Annamil Alvarez-Trotta1,2, Zhiqiang Wang1,3, Elena Shersher1,2, Bin Li1,2, Jun Long1,2, Ines Lohse4,5,6, Claes Wahlestedt4,5, Wael El-Rifai2,3, David J. Robbins1,2,3,* and Anthony J. Capobianco1,2,3,*

1 Molecular Oncology Program, Division of Surgical Oncology, Dewitt Daughtry Family Department of Surgery, University of Miami, Miami, FL, USA

2 Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami, Miami, FL, USA

3 Division of Surgical Oncology, DeWitt Daughtry Family Department of Surgery, Miller School of Medicine, University of Miami, Miami, FL, USA

4 Center for Therapeutic Innovation, Miller School of Medicine, University of Miami, Miami, FL, USA

5 Department of Psychiatry and Behavioral Sciences, Miller School of Medicine, University of Miami, Miami, FL, USA

6 Molecular Therapeutics Shared Resource, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA

* Co-senior authors

Correspondence to:

Anthony J. Capobianco,email: [email protected]
David J. Robbins,email: [email protected]

Keywords: IBET-151; esophageal adenocarcinoma; GDC-0449 resistance; patient-derived xenografts; Hedgehog/GLI signaling pathway

Received: March 29, 2020     Accepted: July 21, 2020     Published: August 18, 2020


The Hedgehog/GLI (HH/GLI) signaling pathway plays a critical role in human oncogenesis. Unfortunately, the clinical use of HH inhibitor(s) has been associated with serious adverse effects and mutation-related drug resistance. Since the efficacy of SMO (Smoothened) and GLI inhibitors is limited in clinical trials, there remains a critical need for the HH/GLI pathway inhibitors with different mechanisms of action. Here, we show that esophageal adenocarcinoma (EAC) cell lines are insensitive to vismodegib (SMO inhibitor) but respond to GANT61 (GLI1 inhibitor). Furthermore, we examine the role of GLI1 in tumorigenicity of EAC and how a selective bromodomain inhibitor IBET-151 downregulates transcriptional activity of the GLI1 transcription factor in EAC. Our study demonstrates that GLI1 plays an important role in tumorigenicity of EAC and that elevated GLI1 expression in patients’ ultrasound-assisted endoscopic biopsy may predict the response to neoadjuvant chemotherapy (NAC) FOLFOX. Importantly, IBET-151 abrogates the growth of vismodegib-resistant EAC cells and downregulates HH/GLI by reducing the occupancy of BRD4 at the GLI1 locus. IBET-151 also attenuates tumor growth of EAC-PDXs and does so in an on-target manner as it reduces the expression of GLI1. We identify HH/GLI signaling as a novel druggable pathway in EAC as well as validate an ability of clinically relevant GLI inhibitor to attenuate the viability of vismodegib-resistant EAC cells. Therefore, we propose that selective bromodomain inhibitors, such as IBET-151, could be used as novel therapeutic agents for EAC patients harboring GLI-dependent tumors.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 27699